Search research articles
Contact Us
Filters
Showing results (131-140 of 139) with videos related to
Page
of 14
Sort By:
You have reached the last page of results.
This site can display upto 139 results.
Journal of Pharmaceutical and Biomedical Analysis
|
January 1, 1991
Measurement of the class III antidysrhythmic drug, UK-68,798, in plasma by radioimmunoassay
D K Walker, G W Aherne, J E Arrowsmith, et al.
Cancer Research
|
July 15, 1993
bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways
T C Fisher, A E Milner, C D Gregory, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 1997
Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase
A L Jackman, R Kimbell, G W Aherne, et al.
British Journal of Cancer
|
July 20, 2000
Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma
H E Ford, D Cunningham, P J Ross, et al.
Oncogene
|
August 19, 2007
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D
S Rayter, R Elliott, J Travers, et al.
Oncogene
|
May 20, 2020
Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D
S Rayter, R Elliott, J Travers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 1999
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines
M J Barnes, E J Estlin, G A Taylor, et al.
British Journal of Cancer
|
October 14, 2005
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points
A O'Donnell, A Padhani, C Hayes, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society
|
May 23, 2000
Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody
B Van Triest, B M Loftus, H M Pinedo, et al.
Page
of 14
Search research articles
Search
Showing results (131-140 of 139) with videos related to
Sort By:
Page
of 14
You have reached the last page of results.
This site can display upto 139 results.
Journal of Pharmaceutical and Biomedical Analysis
|
January 1, 1991
Measurement of the class III antidysrhythmic drug, UK-68,798, in plasma by radioimmunoassay
D K Walker, G W Aherne, J E Arrowsmith, et al.
Cancer Research
|
July 15, 1993
bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways
T C Fisher, A E Milner, C D Gregory, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 1997
Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase
A L Jackman, R Kimbell, G W Aherne, et al.
British Journal of Cancer
|
July 20, 2000
Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma
H E Ford, D Cunningham, P J Ross, et al.
Oncogene
|
August 19, 2007
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D
S Rayter, R Elliott, J Travers, et al.
Oncogene
|
May 20, 2020
Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D
S Rayter, R Elliott, J Travers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 1999
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines
M J Barnes, E J Estlin, G A Taylor, et al.
British Journal of Cancer
|
October 14, 2005
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points
A O'Donnell, A Padhani, C Hayes, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society
|
May 23, 2000
Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody
B Van Triest, B M Loftus, H M Pinedo, et al.
Page
of 14